Two Penny Stocks to watch this week which could be long-term positions:
Adeona Pharmaceuticals, Inc. (AMEX: AEN)
Adeona Pharmaceuticals is now covered by analysts at Chardan Capital Markets. The analysts set a “Buy” rating and a $1.00 price target on the stock.
Adeona Pharmaceuticals, Inc. operates as a pharmaceutical company that develops medicines for central nervous systems. AEN primarily focuses on licensing product candidates that have demonstrated a certain level of clinical efficacy and develop them further to commercial collaboration stage.
AEN is developing various clinical-stage drug candidates that include reaZin, a gastroretentive, sustained-release, and oral tablet formulation of zinc and cysteine for the dietary management of Alzheimers disease and mild cognitive impairment; Trimesta, an investigational oral drug for the treatment of relapsing remitting multiple sclerosis; Effirma, a centrally-acting investigational oral drug for the treatment of fibromyalgia syndrome; and zinc-monocysteine, an oral complex of zinc and the amino acid cysteine for the treatment of age-related macular degeneration.
AEN has a partnership with Meda AB, to develop flupirtine for the treatment of fibromyalgia syndrome.
AEN closed today at $0.59
Celsion Corporation (Nasdaq: CLSN )
Celsion Co. is now covered by analysts at Rodman & Renshaw. The analysts set an “outperform” rating and a $6.00 price target on the stock.
Celsion Corporation, an oncology drug development company, develops and commercializes targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. CLSN is developing its lead product, ThermoDox that is in Phase III clinical trial for primary liver cancer; and in phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a license agreement with Yakult Honsha to commercialize and market ThermoDox for the Japanese market.
CLSN also has a license agreement with Duke University under which it received exclusive rights to commercialize and use Duke’s thermo-liposome technology. In addition, Celsion Corporation has a joint research agreement with Royal Phillips Electronics to evaluate the combination of Phillips’ high intensity focused ultrasound with its ThermoDox to determine the potential of this combination to treat a range of cancers.
CLSN closed today at $2.78
OCT
